Silexion Therapeutics Ltd. (SLXN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Jerusalem, Israel. The current CEO is Ilan Hadar.
SLXN has IPO date of 2024-08-16, 11 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $572.18K.
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
